Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04646356|
Recruitment Status : Recruiting
First Posted : November 27, 2020
Last Update Posted : November 14, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Hereditary Hemorrhagic Telangiectasia Epistaxis Nosebleed||Drug: Tacrolimus capsule (low-dose)||Phase 2|
The aim is to study is to evaluate low-dose tacrolimus as a treatment for HHT. Rare disease presents a number of challenges in clinical trial design, including recruitment challenges, related power limitations and less knowledge about outcomes measurement. Considering these limitations, as well as the large variability in epistaxis measures across HHT patients, a trial design, with each subject receiving the study drug for six months and for one year an epistaxis daily dairy documentation, providing valuable information about seasonal variation.in epistaxis.
This study will investigate tacrolimus, given its demonstrated anti-angiogenic and anti-inflammatory properties, as well as compelling effects in arteriovenous malformation (AVM) models. Specifically, tacrolimus has been shown to oppose the gene expression upregulation of the identified pro-angiogenic markers, thus resulting in anti-angiogenic effects. There are two mechanisms to this. Firstly, recent evidence has shown tacrolimus to be a potent ALK1 signaling mimetic at the transcriptional level. This is particularly significant given that the ALK1 pathway signaling is lost in HHT via the hallmark ACVRL1 and ENG genes. Independent of its effect on the ALK1 pathway, tacrolimus has been shown to be a potent inhibitor of VGEF signaling.
As mentioned previously, the BMP9-ALK1-endoglin-Smad1/5/9 pathway in HHT, is a novel avenue of interest for treating hemorrhage in HHT and also regressing vascular malformations. Given the upstream inactivation of the ALK1 pathway, therapeutic potential via this pathway is dependent on Smad1/5/8 activation and signaling irrespective of the functional status of the corresponding ALK1 receptors. To this end, tacrolimus has been shown to activate Smad1/5/8 signaling in HHT patient-derived cells, thus confirming its therapeutic potential in HHT.
Tacrolimus also has anti-inflammatory effects, via inhibition of pro-inflammatory cytokines, specifically IL2, which is associated with cytotoxic T cell proliferation and activation. Finally, recent evidence also demonstrated a reduction of vascular pathology in mouse models via tacrolimus administration. Tacrolimus also has the advantages of a proven safety track record for long-term use, given its long history in transplant medicine, and can be orally administered, making it more acceptable to patients. In addition to promising effects in laboratory-based studies, Canadian case study reported the regression of angiodysplasia and reduction of mucosal hemorrhage in a probable HHT patient who underwent liver transplantation following high-output cardiac failure and hepatic AVM development. A recent case report of treatment with oral low-dose -dose tacrolimus in an individual with HHT, found that tacrolimus dramatically improved epistaxis. Based on the evidence to date, the investigators hypothesize that oral low-dose tacrolimus will reduce nasal hemorrhage in HHT subjects, through anti-angiogenic and/or anti-inflammatory mechanisms, both of which have been implicated in HHT.
This clinical trial of oral low-dose tacrolimus (0.025mg/kg/day and adjusted to maintain blood levels of 2-5ng/ml 6-month course) in HHT subjects with moderate-severe recurrent nasal hemorrhage. Drug dosing and safety monitoring will be tailored specifically to the agent studied. The primary outcome will be reduction of bleeding minutes per week. In addition, vascular malformation tissue (cutaneous) will be obtained pre and post-investigational product from some subject, and stained for inflammatory, angiogenic and BMP9-ALK1-endoglin- SMAD1/5/9 pathway markers. In addition, pre-excision, vascular malformations will be imaged with speckle variance optical coherence tomography (SVOCT), in vivo non-invasive micro-angiography, to measure lesion structure, vessel volume and vessel density, as previously described. Tissue and imaging may provide important insights into physiological mechanisms that explain clinical changes. If the drugs studied are effective at reducing nasal hemorrhage, this will have important clinical implications for HHT patients.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||Open Label|
|Masking:||None (Open Label)|
|Official Title:||Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT)|
|Actual Study Start Date :||October 20, 2020|
|Estimated Primary Completion Date :||December 2023|
|Estimated Study Completion Date :||September 2024|
Experimental: Tacrolimus immediate-release capsules
subjects will be treated with a 6 months course of oral low-dose tacrolimus capsules to be taken twice daily starting dose of 0.025 mg/kg/day, adjusted to maintain drug blood levels of 2-5ng/ml
Drug: Tacrolimus capsule (low-dose)
low-dose Tacrolimus will be given for 6 months followed by a washout period for 6 months
- The change in epistaxis (nose bleeding) severity using low-dose Tacrolimus [ Time Frame: 96 weeks ]Participants will be asked to maintain a daily diary for the duration of the study (96 weeks). Participants will record all epistaxis events daily, noting the duration in minutes and whether or not there was gushing during each nosebleed. The change in epistaxis severity will be measured from a sum of duration of all bleeding events each week, as measured from the participant daily diary.
- Change in Epistaxis Severity Score (ESS) [ Time Frame: Baseline, Weeks; 12,18,24,30,36,42,48,60,66,72,78,84,96 ]The epistaxis severity score is a six item questionnaire used to calculate a severity of HHT related nose bleeding. Each question is pertaining to the subject's typical symptoms within the last 3 months period. The first three questions are related to frequency, duration and intensity. The forth question whether or not medical attention was sought for nose bleeding. The remaining two questions are related to the presence of anemia and the need for blood transfusion due to nose bleeding. The resulting epistaxis severity score vary between; none 0-1, mild bleeding >1-4, moderate bleeding >4-7 and >7-10 for severe bleeding. The ESS questionnaire will be administered to participants at every clinic visit throughout the 96 weeks of the study.
- Change in Chronic Bleeding [ Time Frame: Baseline, Weeks; 12,18,24,30,36,42,48,60,66,72,78,84,96 ]Blood samples will be taken to measure change in chronic bleeding as a safety measure. Samples will be taken prior to investigational product for a baseline value. This will be followed by measurements every six weeks during the periods of investigational product for comparative analysis
- Micro-Imaging to measure regression of Vascular Malformations [ Time Frame: week 12, week 36, week 60, week 84 ]Telangiectases will be micro-imaged using an established medical imaging technique speckle variance optical coherence tomography (SVOCT). The micro-imaging will be used for vasculature measurements and structural images of the telangiectases.
- The use of Telangiectasia tissue sample to look at the mechanisms of action of Tacrolimus [ Time Frame: week 36, week 84 ]A punch biopsy of one cutaneous telangiectasia will be performed at two time points during the study. The biopsy tissue sample will be taken at the end of each 6 month active comparator treatment. The tissue will be analyze and stained for inflammatory, angiogenesis and BMP9-ALK1-endoglin-Smad1/5/9 pathway markers (VEGF, MMP-9, COX-2, Endoglin, ALK1 ) before and after treatment with Tacrolimus
- Change in Biomarkers [ Time Frame: Weeks: 12, 24, 36, 48, 60, 72, 84, 96 ]In order to understand the mechanisms of Tacrolimus effects on vascular malformations and hemorrhage in HHT a serum/plasma sample will be collected before and after treatment with Tacrolimus to measure inflammatory, angiogenesis and BMP9-ALK1-endoglin-Smad1/5/9 pathway markers (VEGF, MMP-9, Thrombospondin-2, ESR, CRP, endothelin)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Age > 18 years
- Clinical HHT diagnosis or personal genetic diagnosis of HHT
- Epistaxis at least 15 min per week (mean for past month)
- At least one telangiectasia (skin or mucosal) available for micro-imaging.
- Ability to give written informed consent, including compliance with the requirements of the study.
- Allergy/intolerance to the study drug or related agents
- Unstable medical illness
- Acute infection
- Creatinine > ULN (upper limit of normal)
- Liver transaminases (AST or ALT) >= 2x ULN
- Women participant who are pregnant or breastfeeding or plan to become pregnant during the duration of the study
- Women of childbearing potential not on effective contraception. Male participants of reproductive potential whose female partners are of childbearing potential and are not planning to use highly effective contraceptive method
- BHCG level <6 IUL (re-test if 6-24 IU/L)
- Specific contra-indications for study drug (detailed in the product monograph)
- Abnormal ECG where the QTc >480msec
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04646356
|Contact: Negar Bagheri, BSc MScemail@example.com|
|St. Michael's Hospital||Recruiting|
|Toronto, Ontario, Canada, M5B1W8|
|Contact: Marie E Faughnan, MD MSc FRCP 416-864-6060 ext 5412 firstname.lastname@example.org|
|Contact: Negar Bagheri, BSc MSc 416-930-1334 email@example.com|
|Principal Investigator: Marie E Faughnan, MD|
|Principal Investigator:||Marie E Faughnan, MD,MSc,FRCPC||Unity Health Toronto|
|Responsible Party:||Unity Health Toronto|
|Other Study ID Numbers:||
|First Posted:||November 27, 2020 Key Record Dates|
|Last Update Posted:||November 14, 2022|
|Last Verified:||November 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
|Product Manufactured in and Exported from the U.S.:||No|
Hereditary Hemorrhagic Telangiectasia
Telangiectasia, Hereditary Hemorrhagic
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Physiological Effects of Drugs
Molecular Mechanisms of Pharmacological Action